Clinical Trial Update: Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert [Phase 4]

View source ↗

Summary

A Phase 4 postmarketing study evaluating the immunogenicity of Berinert in patients with hereditary angioedema (types I and II) has been completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Berinert (C1 esterase inhibitor)

Snippet

Sponsor: CSL Behring | Conditions: Hereditary Angioedema Types I and II | Phase 4 | Status: COMPLETED | Results posted: 2015-11-16